Medtronic to Acquire Medicrea
Medicrea announced that it entered into an agreement to be acquired by Medtronic at a price of €7 (USD $8.01) per share with a 2020 estimated close date. Jul 15, 2020
2Q Earnings Preview: COVID’s Continued Spread Complicates Orthopedic Market Recovery
We expect 2Q20 orthopedic performance above consensus projections, but the U.S.’s inability to check the spread of COVID-19 will slow market recovery. Jul 14, 2020
COVID-Proof Orthopedic Trends That Will Shape the Market in 2021
Increasing adoption of enabling technology, company consolidation through M&A, and accelerating growth of outpatient centers are COVID-proof orthopedic trends that will shape the market in 2021 and beyond. Jun 17, 2020
Orthopedic Market Forecast Through 2022
Despite the uncertainty brought on by COVID-19, we’ve looked ahead and developed our orthopedic market forecast and trends through 2022. Jun 10, 2020
Patient Confidence Improving but Situation Remains Fluid
Patient sentiment and confidence will play a key role in the COVID-19 orthopedic procedure recovery. What can we learn about patients from the data? Jun 02, 2020
Medtronic Anticipates More Severe Declines in Coming Months
The company’s orthopedic revenues for its fiscal fourth quarter fell -35% as it endured an additional month of COVID-related impact in April compared to competitors. May 26, 2020
Seikagaku Grows in FY19 on Strength in U.S. Market
The company grew in FY19 despite COVID-related declines in its fourth quarter, driven by both reimbursement wins and competitive account conversions. May 21, 2020
Orthopedics to Take Unprecedented Hit from COVID-19, Market Fundamentals Remain Strong
The underlying fundamentals of the orthopedic industry remain unchanged due to COVID-19. However, we should prepare for significant alterations in the market landscape as well as the ways that we interact with colleagues and customers. May 19, 2020
SeaSpine to Pursue Aggressive Launch Cadence Despite COVID-19
The company was able to offset deeper COVID-related declines on the strength of its advanced DBM portfolio and plans to pursue several alpha launches of new products in 2020. May 14, 2020
Conformis Gets Battered by COVID-19 Procedure Deferrals
Geographic factors and a highly elective portfolio exposed the company to a severe downturn due to COVID-19, with 1Q20 revenue down 20% and April revenues down 95%. May 14, 2020
